Cargando…

Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)

Durvalumab (anti-programmed cell death ligand-1) administration after concurrent chemoradiotherapy (cCRT) has improved the survival of patients with unresectable, locally advanced (LA) stage III non-small cell lung cancer (NSCLC). Some patients are unable to complete cCRT and cannot receive immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tachihara, Motoko, Tsujino, Kayoko, Ishihara, Takeaki, Hayashi, Hidetoshi, Sato, Yuki, Kurata, Takayasu, Sugawara, Shunichi, Okamoto, Isamu, Teraoka, Shunsuke, Azuma, Koichi, Daga, Haruko, Yamaguchi, Masafumi, Kodaira, Takeshi, Satouchi, Miyako, Shimokawa, Mototsugu, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684372/ https://www.ncbi.nlm.nih.gov/pubmed/34934361 http://dx.doi.org/10.2147/CMAR.S336262

Ejemplares similares

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
por: Sakai, Kazuko, et al.
Publicado: (2020)

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
por: Tachihara, Motoko, et al.
Publicado: (2023)

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
por: Shiraishi, Yoshimasa, et al.
Publicado: (2022)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

Prevalence of back pain and the knowledge of preventive measures in a cohort of 11619 Polish school-age children and youth—an epidemiological study
por: Kędra, Agnieszka, et al.
Publicado: (2019)

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)
por: Ishii, Hidenobu, et al.
Publicado: (2022)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
por: Wakuda, Kazushige, et al.
Publicado: (2023)

Glucose metabolism‐targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor‐induced drug‐tolerant persisters
por: Kunimasa, Kei, et al.
Publicado: (2017)

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
por: Kiura, Katsuyuki, et al.
Publicado: (2018)

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
por: Sakata, Shinya, et al.
Publicado: (2021)

Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer
por: Fukuda, Kiyoko, et al.
Publicado: (2023)

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer
por: Sekine, Ikuo, et al.
Publicado: (2016)

Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)
por: Yokoe, Takamichi, et al.
Publicado: (2021)

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
por: Akamatsu, Hiroaki, et al.
Publicado: (2022)

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
por: Shimokawa, Mototsugu, et al.
Publicado: (2020)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022)

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
por: Kato, Ryoji, et al.
Publicado: (2020)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Isolation of antifungal-resistant Candida from the blowholes of captive dolphins
por: SHIRAKATA, Chika, et al.
Publicado: (2022)

The dolphin
Publicado: (1981)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
por: Shitara, Kohei, et al.
Publicado: (2016)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)
por: Takeda, Masayuki, et al.
Publicado: (2012)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Whales and dolphins /
por: Martin, Anthony R.
Publicado: (1990)

Dolphins and whales
por: Savage, Stephen, 1965-
Publicado: (1990)

Lilly on Dolphins/
por: Cunningham, Lilly John

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
por: Sasaki, Tomonari, et al.
Publicado: (2018)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2020)

First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
por: Satouchi, Miyako, et al.
Publicado: (2021)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
por: Wakuda, Kazushige, et al.
Publicado: (2020)

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
por: Nagano, Tatsuya, et al.
Publicado: (2018)

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2022)

Whales, dolphins and porpoises /
por: Carwardine, Mark
Publicado: (2002)

Whales, dolphins, and porpoises /
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_2887drtacupp4htr4l19in37q9